Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.69 USD | +0.81% | +18.72% | +48.46% |
04-19 | TScan Therapeutics Closes $150.1 Million Securities Offering | MT |
04-17 | TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants | MT |
Business Summary
Number of employees: 154
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
T Cell Receptor-engineered T Cell
100.0
%
| 14 | 100.0 % | 21 | 100.0 % | +55.52% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 14 | 100.0 % | 21 | 100.0 % | +55.52% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Jason Amello
DFI | Director of Finance/CFO | 55 | 01-28 |
Justin McCue
CTO | Chief Tech/Sci/R&D Officer | - | 12-03 |
Ray Lockard
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-05 |
Chief Tech/Sci/R&D Officer | - | - | |
Heather Savelle
IRC | Investor Relations Contact | - | 21-10-04 |
Leiden Dworak
AUD | Comptroller/Controller/Auditor | - | 22-04-10 |
Zoran Zdraveski
LAW | General Counsel | 54 | 21-09-08 |
Ann Hargraves
HRO | Human Resources Officer | - | 20-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 76 | 19-02-28 | |
Stephen Biggar
BRD | Director/Board Member | 53 | 21-02-28 |
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Barbara Klencke
BRD | Director/Board Member | 66 | 23-04-05 |
Katina Dorton
BRD | Director/Board Member | 66 | 21-03-22 |
R. Woods
BRD | Director/Board Member | 57 | 12-05 |
Gabriela Gruia
BRD | Director/Board Member | 67 | 21-05-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 4,276,588 | 0 | 0 | 90.24 % |
Stock B | 1 | 43,628,149 | 43,231,132 ( 99.09 %) | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.46% | 493M | |
+20.59% | 42.68B | |
-2.98% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.83% | 24.94B | |
-19.84% | 18.96B | |
+30.30% | 12.3B | |
-2.69% | 11.95B | |
-2.93% | 11.55B |
- Stock Market
- Equities
- TCRX Stock
- Company TScan Therapeutics, Inc.